Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02909452 | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Syndax PharmaceuticalsINDUSTRY | 1 | Jan 25, 2022 | clinicaltrials |
| NCT02403193 | Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)(AdenONCO) | completed | Phase 1 | 92 | Palobiofarma SLINDUSTRY | 1 | Jan 12, 2022 | clinicaltrials |
| NCT03514719 | PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)(PINNACLE) | completed | Phase 1 | 24 | Radboud University Medical CenterOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT02938624 | Anti PD-1 Neo-adjuvant Treatment for NSCLC(MK3475-223) | completed | Phase 1 | 28 | Jair Bar, M.D., Ph.D.OTHER_GOV | 1 | Dec 14, 2021 | clinicaltrials |
| NCT00730639 | A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies(MDX1106-03) | completed | Phase 1 | 395 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT01594398 | Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer(ENCORE110) | completed | Phase 1 | 14 | Syndax PharmaceuticalsINDUSTRY | 1 | Nov 19, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT01757288 | Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC | completed | Phase 1 / Phase 2 | 98 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT01911507 | INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 | 35 | University of California, DavisOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT01586624 | A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1) | completed | Phase 1 | 61 | Cancer Research UKOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT01449461 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) | completed | Phase 1 / Phase 2 | 137 | Ariad PharmaceuticalsINDUSTRY | 0 | Aug 17, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02964689 | Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. | completed | Phase 1 | 18 | Swiss Cancer InstituteOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT02197247 | Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 6 | Jul 12, 2021 | clinicaltrials |
| NCT01840579 | Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | completed | Phase 1 | 57 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT01076231 | Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery | completed | Phase 1 / Phase 2 | 34 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT00452413 | A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | completed | Phase 1 / Phase 2 | 65 | Eli Lilly and CompanyINDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT01199068 | CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 15 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT02574078 | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)(CheckMate370) | completed | Phase 1 / Phase 2 | 341 | Bristol-Myers SquibbINDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT03380871 | A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | completed | Phase 1 | 38 | BioNTech US Inc.INDUSTRY | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02897765 | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | completed | Phase 1 | 34 | BioNTech US Inc.INDUSTRY | 1 | Feb 25, 2021 | clinicaltrials |
| NCT02952729 | Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 | completed | Phase 1 | 120 | Mersana TherapeuticsINDUSTRY | 1 | Feb 24, 2021 | clinicaltrials |
| NCT02447900 | Marker Guided Breathhold Radiotherapy in NSCLC | completed | Phase 1 | 15 | Steen Riisgaard MortensenOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT02668393 | Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma | completed | Phase 1 | 14 | Boehringer IngelheimINDUSTRY | 2 | Jan 29, 2021 | clinicaltrials |
| NCT02572687 | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | completed | Phase 1 | 85 | Eli Lilly and CompanyINDUSTRY | 8 | Jan 20, 2021 | clinicaltrials |
| NCT02793856 | PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer | completed | Phase 1 | 12 | Sichuan UniversityOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT00434174 | Safety of Everolimus and Pemetrexed in Lung Cancer Patients | completed | Phase 1 | 48 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 21, 2020 | clinicaltrials |
| NCT00456833 | Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy | completed | Phase 1 | 248 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 21, 2020 | clinicaltrials |
| NCT00535951 | Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT01772797 | Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer | completed | Phase 1 | 22 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 19, 2020 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02292550 | Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. | completed | Phase 1 | 27 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 17, 2020 | clinicaltrials |
| NCT00674102 | An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 9, 2020 | clinicaltrials |
| NCT01999985 | Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT01958372 | Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer | completed | Phase 1 | 11 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT00821951 | Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer | completed | Phase 1 | 17 | Yale UniversityOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04006301 | First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation | completed | Phase 1 | 10 | Janssen Research & Development, LLCINDUSTRY | 2 | Nov 6, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00832117 | Phase I Combination Ixabepilone + Cisplatin | completed | Phase 1 | 30 | R-PharmINDUSTRY | 2 | Oct 28, 2020 | clinicaltrials |
| NCT02879760 | Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 16 | Turnstone Biologics, Corp.INDUSTRY | 1 | Oct 6, 2020 | clinicaltrials |
| NCT02451930 | A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC | completed | Phase 1 | 71 | Eli Lilly and CompanyINDUSTRY | 4 | Oct 5, 2020 | clinicaltrials |
| NCT02079636 | A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) | completed | Phase 1 | 142 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 11, 2020 | clinicaltrials |
| NCT01189968 | A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 | 50 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 9, 2020 | clinicaltrials |
| NCT01784640 | Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer | completed | Phase 1 | 13 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT03450330 | Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer(JACKPOT1) | completed | Phase 1 / Phase 2 | 10 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 24, 2020 | clinicaltrials |
| NCT02411591 | A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 66 | Eli Lilly and CompanyINDUSTRY | 3 | Jul 9, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 25, 2022source: clinicaltrials